Enlivex Therapeutics Ltd. (ENLV) is a clinical stage immunotherapy company that specializes in the development of a novel therapeutic platform for treating significant unmet clinical needs linked with severe sepsis and septic shock, as well as hyper-immune and acute immune over-responses caused by disorders such as COVID-19 and Graft vs. Host Disease (GvHD).
The company is headquartered in Israel and is publicly traded on the Nasdaq Global Market under the ticker symbol ENLV. Enlivex Therapeutics prides itself in harnessing the body's innate immune system to address a broad range of inflammatory and immune-related conditions. Their innovative approach is geared towards restoring immune balance, thus providing an exciting new path in the battle against immune system disorders.
At the cutting edge of their research is Allocetra, their leading drug candidate, which is formulated to restore a safe immune balance by controlling over-active immune response. Allocetra operates by modulating the immune system's activity to stimulate the immune response in conditions where it's underperforming and suppress it in conditions where it's overreacting. This therapy is currently under evaluation in Phase II clinical trials for treating severe and critical COVID-19 patients, as well as in a planned Phase II/III clinical trial in sepsis.
In addition, Enlivex has a positive track record in clinical development. Their clinical trials have shown marked success, boosting the company's reputation in the medical field. They have continuously championed scientific research and development, investing significantly in cutting-edge technology and innovation.
The company also aspires to establish Allocetra as a pipeline platform with the potential to treat a variety of other diseases characterized by an imbalanced immune response. Some of these include autoimmune diseases and cancer.
Overall, Enlivex Therapeutics Ltd. symbolizes a pioneer in the field of immunotherapies, continually driving progress and contributing to advancements in modern medicine. Their dedication to providing advanced treatment solutions in areas of unmet medical needs is a testament to their commitment to improving patients' lives. Through their innovative therapeutic strategies, they are setting new standards in the fight against some of the world's most dangerous diseases.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Enlivex Ltd. announced that 135 out of a planned 182 patients have been randomized and received the first injection of Allocetra™ in its Phase 2b clinical trial for moderate-to-severe age-related symptomatic primary knee osteoarthritis. Enrollment is ongoing in the U.S. and Europe, with topline six-month data expected by mid-2027. This trial builds on positive Phase 1/2a data that led to FDA Regenerative Medicine Advanced Therapy (RMAT) designation.
Enlivex Ltd. (NASDAQ: ENLV) is planning to appeal a Nasdaq delisting notice triggered by its failure to meet the US$1 minimum bid rule. The company is implementing a 1-for-16 reverse stock split effective October 27 to support its appeal and regain compliance. While a timely appeal request would allow continued trading on Nasdaq, Enlivex cannot guarantee the success of its appeal or continued listing.